73.27 USD
↘ 0.82 (1.11%)AT CLOSE (11:59 AM EDT)
Ionis Pharmaceuticals, Inc. Common Stock
IONSNASDAQ • USD
73.31
↗ 0.04 (0.05%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
73.31
↗ 0.04 (0.05%)
Market: CLOSED
Open?$74.09
High?$74.51
Low?$72.33
Prev. Close?$74.09
Volume?1.8M
Avg. Volume?1.9M
VWAP?$73.29
Rel. Volume?0.95x
Bid / Ask
Bid?$72.00 × 300
Ask?$73.27 × 200
Spread?$1.27
Midpoint?$72.63
Valuation & Ratios
Market Cap?12.1B
Shares Out?165.2M
Float?157.0M
Float %?95.1%
P/E Ratio?N/A
P/B Ratio?24.73
EPS?-$2.31
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?3.83Strong
Quick Ratio?3.81Strong
Cash Ratio?0.48Low
Debt/Equity?3.64High
ValuationRICHLY VALUED
Score50/100
P/E?N/A▾
P/B?24.73HIGH▾
P/S?12.82HIGH▾
P/FCF?N/A▾
EV/EBITDA?-36.3CHEAP▾
EV/Sales?14.31HIGH▾
Returns & Efficiency
ROE?-78.0%WEAK▾
ROA?-10.8%WEAK▾
Cash Flow & Enterprise
FCF?$-320027000
Enterprise Value?$13.5B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Address
2855 GAZELLE COURT
CARLSBAD, CA 92010
Phone: (760) 931-9200
CARLSBAD, CA 92010
Phone: (760) 931-9200